1Bradstedt DC. Comparative tolerability profile of omeprazole in clinical trials[J]. Dig Dis Sci, 1995, 36(7) : 1384-1391. 被引量：1
2Mc-Tavish D, Buckley MT, Heel RC. Omeprazole: An updated review of its pharmacology and therapeutic use in acld-related dlsorders[J]. Drugs, 1995,42(2) : 138-170. 被引量：1
3Tateno M, Nakamura N. Phase Ⅰ study of lansoprazole (AG- 1749) antiulcer agent[J]. Capsule form Rinsho Iyaku, 1996, 7 (1) : 51-62. 被引量：1
4Mignon M, Hochlaf S, Forestier S, et al. Acid inhibitory effect of graded dose of lansoprazole in patients with Z-E syndrome [ J]. Gastroenterologie Clinique et Biolo-gique, 1998, 18(1) : 13- 16. 被引量：1
5Wormsley KG. Efficacy and safety of long-term maintenance therapy of duo denal ulcers[J]. Scand J Gastroenterol, 1999, 24 (Suppl 16) : 1145-1152. 被引量：1
6Barradell LH, Faulds D, Mc Tavish D. Lansoprazole: A review of its pharmaco-dynarnic and pharmacokinetic-properties and its therapeutic efficacy in acid-related disorders[J]. Drugs, 1996, 44(3) :225-250. 被引量：1
7Patel P, Nakamur T, Joubert M, et al. Helicobacter pylori infection in childhood, risk factors and effect on growth[J]. BMJ, 1999, 309(6) : 1119-1123. 被引量：1
8Bigard MA, Joubert M, De Meynard C. Complete prevention by lansoprazole of asprin induced gastric lesions in healthy subjects [ J ]. Gastroenterology, 1995,100 ( 1 ) : A34. 被引量：1
9Craanen ME, Hamilton MR. Helicobacter pylori and early gastric cancer[J]. Gut, 1994, 35(7) : 1372-1374. 被引量：1
10Banatvala N, Pounder RE, Hamilton MR, et al. High prevalence of Helicobaeter pylori metronidazole resistanee in migrants to east logeon: relation with previous nltroimidazole exposure and gastroduodenal disease[J]. Gut, 1999, 35(8) : 1562-1566. 被引量：1
